
**Aerosol drug delivery device design
verification — Requirements and test
methods**

*Vérification de la conception d'un dispositif d'administration de
médicament sous forme d'aérosol — Exigences et méthodes d'essai*



Reference number
ISO 20072:2009(E)

© ISO 2009

PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.



COPYRIGHT PROTECTED DOCUMENT

© ISO 2009

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

Page

Foreword.....	iv
Introduction	v
1 Scope	1
2 Normative references	1
3 Terms and definitions	2
4 Symbols and abbreviated terms	6
5 Requirements	7
5.1 General.....	7
5.2 Risk assessment requirements.....	8
5.3 Device functionality profile.....	8
5.4 System verification test	8
5.5 Uncertainty of measurements and conformance with specification.....	9
5.6 Test requirements.....	9
6 Test methods.....	11
6.1 General.....	11
6.2 Test procedures	12
6.3 Test conditions	16
6.4 Test evaluations.....	17
7 Test report	19
8 Information supplied by the manufacturer	19
8.1 General.....	19
8.2 Marking	19
8.3 Instructions for use	20
Annex A (informative) Rationale for requirements	22
Annex B (informative) Further guidance and clarification of the device functionality profile	24
Annex C (informative) Rationale for test methods.....	26
Annex D (informative) Two-sided tolerance limit factors (<i>k</i>).....	29
Annex E (informative) Alternative acceptance criteria for the device functionality profile evaluation	35
Bibliography	42

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 20072 was prepared by Technical Committee ISO/TC 84, *Devices for administration of medicinal products and intravascular catheters*.

Introduction

This International Standard applies to hand-held aerosol drug delivery devices (ADDD) intended to administer medication to humans. To avoid unnecessarily restricting innovation, given the broad variation in device designs, this International Standard addresses the more general design/labelling requirements rather than specific physical and prescriptive design requirements. However, this International Standard does require the elaboration of a device functionality profile (DFP) specific to the ADDD in question. This International Standard also addresses ADDD design requirements from both the user interface and safety perspectives.

An ADDD is used as part of a system consisting of the ADDD, the container, the medication and the labelling, including the instructions for use. Therefore, design verification of the ADDD includes a final system verification test conducted in accordance with the instructions for use.

From a regulatory perspective, the ADDD system may be reviewed and approved as part of a drug product (combination of ADDD and medication) or as a device by itself. For the purposes of this International Standard, such regulatory distinctions do not alter the intent of the design verification process described herein. As an example, in the European Union (EU), if an ADDD is placed on the market in such a way that the ADDD and the medication form a single integral product (i.e. the system) that is intended exclusively for use in the given combination and which is not refillable, that single product shall be governed by Directive 2001/83/EEC. However, the relevant essential requirements of Annex I of the Medical Device Directive (93/42/EEC) shall apply as far as safety and performance-related ADDD features are concerned, which is the specific objective of this design verification standard.

Regardless of the distinctions (“drug” or “device,” pre-filled or refillable), it is recognised that ADDD design verification is an important component of the overall validation process. Moreover, design verification is iterative, to be conducted at various phases throughout the ADDD’s development and subsequent ADDD post-approval modifications. In all instances, design verification is conducted using the phase-appropriate instructions for use. It is understood that in the early phases of ADDD development an appropriate subset of the requirements contained herein might apply, but that all of the requirements will be satisfied as part of the final design verification exercise. Furthermore, design verification should be considered a minimum requirement for the safe and effective use of the ADDD, and in many instances additional testing may be appropriate as indicated by a risk assessment that shall also be conducted.

This International Standard introduces the requirement for developers and/or manufacturers to create a device functionality profile (DFP) for a given ADDD based on the ISO Standard for device risk assessment (as a part of ISO 14971). The device functionality profile defines the parameters and tolerance intervals used to verify the ADDD’s ability to meet the manufacturer’s design specifications during in-use conditions and following environmental and electromechanical extreme use conditions. This International Standard also includes a system verification test conducted at standard atmosphere and nominal flow rate as a simple bridge between the device design and the patient interface.

The purpose of this International Standard is to ensure a method and guide for independent testing of the repeatability and reproducibility of ADDD functionality that verifies compliance with its design specification. The design verification process may include use of applicable regulatory agency requirements and/or test methods. The sampling plans for this International Standard are intended to verify the design at a high confidence level. They do not replace the more general manufacturing quality systems, including lot release, which appear in standards on quality systems (e.g. the ISO 9000 series or ISO 13485).

Figure 1 illustrates the process this International Standard advises to use in order to assess and verify whether a design meets the determined DFP.




Figure 1 — ADDD design verification process

This International Standard specifically addresses the most basic elements regarding the safe and effective use of ADDD in humans. It does not define the pharmaceutical or clinical performance of an ADDD. Any labelling indicating ADDD use to deliver medication to specific regions of the respiratory tract falls under the authority of national governments or regional agencies regulating the manufacture and marketing of medical devices and pharmaceutical products. In some countries national regulations exist, and their requirements can supersede or complement this International Standard.

For a given manufacturer, existing marketed products and those currently under development might not fulfil some of the requirements. However, manufacturers should comply with this International Standard when improving the functional design of existing ADDDs or developing new ADDDs to obtain an even higher level of quality.

Annex A describes the reasoning for establishing the various requirements in this International Standard.

Aerosol drug delivery device design verification — Requirements and test methods

1 Scope

This International Standard applies to the design, labelling, instructions for use and testing requirements for hand-held single- and multi-use aerosol drug delivery devices (ADDDs) intended to deliver a metered or pre-metered aerosolized medication to or by means of the human respiratory tract (including nasal, oral, tracheal, bronchial and alveolar sites). This International Standard applies to both refillable and disposable devices intended for personal use.

This International Standard is intended for device design verification and not for drug product quality assessment. The objective of this International Standard is to verify, by laboratory (*in-vitro*) testing, that the ADDD design consistently meets the manufacturer's design specification by satisfying a device functionality profile and system verification test both of which are determined from a risk assessment and evaluated in accordance with the instructions for use.

This International Standard excludes continuous or semi-continuous aerosolization devices covered in ISO 27427, aerosolization devices which do not emit active pharmaceutical ingredient (API), general purpose aerosolization devices (for use with ventilators) and atomizers.

This International Standard does not apply to manufacturers of single parts or components of the ADDDs [e.g. (spray) pumps, valves, containers, etc.].

NOTE There might be times when a device falls under the scope of this International Standard and that of ISO 27427. The committee envisions that the intended use of the product and the risk assessment of the device will derive which International Standard the manufacturer chooses for design verification of the ADDD. This International Standard outlines the process by which ADDD design verification is to be performed in conjunction with a risk-based device functionality profile of the ADDD with either the medication, a placebo or a representative medication. ISO 27427 outlines the process by which the characterization of the aerodynamic aerosol performance of a nebulizing system for use with a non-specific class of active pharmaceutical ingredient(s) is made.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 14971:2007, *Medical devices — Application of risk management to medical devices*

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing*

ISO 11135-1, *Sterilization of health care products — Ethylene oxide — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO 11137 (all parts), *Sterilization of health care products — Radiation*

ISO 15223-1, *Medical devices — Symbols to be used with medical device labels, labelling and information to be supplied — Part 1: General requirements*

ISO 20072:2009(E)

ISO 17665-1, *Sterilization of health care products — Moist heat — Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*

IEC 60068-2-27, *Environmental testing — Part 2-27: Tests — Test Ea and guidance: Shock*

IEC 60068-2-30:2005, *Environmental testing — Part 2-30: Tests — Test Db: Damp heat, cyclic (12 h + 12 h cycle)*

IEC 60068-2-32, *Environmental testing — Part 2: Tests. Test Ed: Free fall*

IEC 60068-2-64, *Environmental testing — Part 2-64: Tests — Test Fh: Vibration, broadband random and guidance*

IEC 60601-1, *Medical electrical equipment — Part 1: General requirements for basic safety and essential performance*

IEC 60601-1-2, *Medical electrical equipment — Part 1-2: General requirements for basic safety and essential performance — Collateral standard: Electromagnetic compatibility — Requirements and tests*

IEC 60601-1-8, *Medical electrical equipment — Part 1-8: General requirements for basic safety and essential performance — Collateral standard: General requirements, tests and guidance for alarm systems in medical electrical equipment and medical electrical systems*

IEC 60721-3-7, *Classification of environmental conditions — Part 3-7: Classification of groups of environmental parameters and their severities — Portable and non-stationary use*

IEC 61000-4-2, *Electromagnetic compatibility (EMC) — Part 4-2: Testing and measurement techniques — Electrostatic discharge immunity test*

IEC 61000-4-3, *Electromagnetic compatibility (EMC) — Part 4-3: Testing and measurement techniques — Radiated, radio-frequency, electromagnetic field immunity test*

IEC 62304, *Medical device software — Software life-cycle processes*

IEC 62366, *Medical devices — Application of usability engineering to medical devices*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

**3.1
accessory**
add-on device (specifically referenced in the ADDD instructions for use) that may be used in conjunction with an ADDD to enable or enhance its performance

EXAMPLE Spacers, holding chambers, actuation counters, content indicators, etc.

**3.2
active pharmaceutical ingredient
API**
molecule(s) responsible for producing the intended therapeutic action

**3.3
actuation**
operation of the ADDD to release medication that will be aerosolized

NOTE The actuation can consist of the loading and release of the medication or only the release of the medication.

3.4**actuation counter
dose counter**

mechanism numerically counting down the number of actuations

NOTE The actuation counter may either be an accessory or integrated with the ADDD.

3.5**ADDD system**

integrated system comprised of the ADDD, patient interface and the medication (i.e. a combination product)

3.6**aerosol**

suspension of particles in gas

[ISO 27427:2009, definition 3.1]

NOTE 1 Particles can be liquid and/or solid.

NOTE 2 The gas can be the driving gas or ambient air.

3.7**aerosol drug delivery device****ADDD**

device for the delivery of medication in the form of an aerosol

3.8**claimed lifetime**

time period, and/or number of actuations, stated by the ADDD manufacturer within which the device functionality profile of the ADDD will remain within the design specification comprising the timeframe within which the patient uses the ADDD

NOTE Claimed lifetime is not necessarily the same as the shelf life of the ADDD.

3.9**claimed lifetime testing**

performance evaluation simulating the claimed lifetime stated by the ADDD manufacturer within which the device functionality profile of the ADDD will remain within the design specification

3.10**combination product**

ADDD used with a specific medication

3.11**content indicator**

visual indicator showing the amount of medication remaining in the ADDD

NOTE A content indicator can be either an accessory or integrated with the ADDD.

3.12**design verification**

confirmation by examination and provision of objective evidence that specified design requirements have been fulfilled

3.13**device functionality profile****DFP**

parameters and tolerance intervals used to assess whether the ADDD meets the manufacturer's design specification

NOTE It must be possible to evaluate the properties using laboratory (*in vitro*) testing.

3.14

dose

mass of API prescribed to elicit a therapeutic response

NOTE 1 More than one actuation of the ADDD may be required to achieve the specified dose.

NOTE 2 For certain APIs, mass can be replaced by the use of biological equivalent units.

3.15

emitted mass

EM

mass of medication per actuation emitted from the ADDD mouthpiece at the patient interface

3.16

excipient

any substance included with the active pharmaceutical ingredient(s) of the medication

3.17

fixed-dose ADDD

ADDD where the amount of medication delivered per actuation (mass or bioequivalent units), either pre-metered or from a reservoir, is pre-set by the manufacturer

3.18

hand-held

capable of being held in the hand and moved to the patient's mouth or nose for use

3.19

harm

physical injury or damage to the health of people, or damage to property or the environment

[ISO 14971:2007, definition 2.2]

3.20

holding chamber

accessory comprising a volume between the ADDD and the patient's mouth or nose and designed to contain the aerosol following an actuation

NOTE A holding chamber has some means for retaining the aerosol after ADDD actuation has occurred and prior to the patient inhaling.

3.21

instructions for use

directions provided by the manufacturer for the correct handling and operation of the ADDD

3.22

integral supply of medication

manufacturer-sealed supply of medication contained by or provided to an ADDD

EXAMPLE Reservoirs or blisters.

3.23

intended use

application of the ADDD that is specified by the manufacturer in the instructions for use

3.24

in-use life

time specified by the manufacturer that the medicinal product can be used after opening or after first use by the patient

3.25**label**

text (printed or graphic) affixed to or present (etched) on or accompanying the ADDD

3.26**label claim**

amount of API (mass) marked on the label of the ADDD

NOTE In some countries the label claim is the amount of API that is emitted from the ADDD mouthpiece. In other countries the label claim might be the amount of API that is metered by the ADDD, but not necessarily all emitted from the mouthpiece of the ADDD.

3.27**medication**

API(s) alone or API(s) formulated with excipients(s)

3.28**medicinal product**

the medication in the ADDD

3.29**nasal delivery**

administration of medication to or through the nose

3.30**nominal flow rate**

volumetric air flow rate through the ADDD which is described by the manufacturer as typical for the intended patient population

3.31**operator**

person (patient/user) using the ADDD

3.32**oral delivery**

administration of medication to or through the mouth

3.33**placebo**

dosage form that does not contain API

3.34**pre-filled**

ADDD in which the medication is inserted at manufacture and cannot be replenished by the patient

3.35**pre-metered**

defined amount of medication equal to one actuation placed during its manufacture into a package (blister, capsule) for use in the ADDD

3.36**primary packaging container**

the container in which the medication is enclosed

3.37**refillable ADDD**

designed to be replenished with medication for further operation

3.38

respiratory tract

anatomical region comprising nasal, oral, pharyngeal, tracheal, bronchial and alveolar regions

3.39

risk

combination of the probability of occurrence of harm and the severity of that harm

[ISO 14971:2007, definition 2.16]

3.40

risk assessment

RA

overall process comprising a risk analysis (estimation) and a risk evaluation

[ISO 14971:2007, definition 2.18]

3.41

secondary packaging

container in which the ADDD is enclosed

3.42

selected-dose ADDD

device where the amount of medication delivered per actuation (mass or bioequivalent units), either pre-metered or from a reservoir, is set by the operator

3.43

size distribution

relationship between weighting (by number, surface area, volume or mass) and size that describes the population of aerosol particles or droplets

3.44

spacer

accessory that increases the distance between the ADDD and the patient's mouth or nose

3.45

system verification test

test of the ADDD system conducted after successfully satisfying the device functionality profile

3.46

visible defects

observable imperfections that prevent the ADDD either from meeting its device functionality profile or from being safe to use

4 Symbols and abbreviated terms

P_T For a given ADDD device functionality profile, the parameter of interest (e.g. flow path resistance) and the target value (per the design specification) being evaluated.

k Tolerance limit factor – determined from the confidence level, probability content, p , and the number of measurements, n , conducted for each P_T .

p Probability content.

n Number of ADDDs required for a given test.

\bar{x} The sample average – based on a random sample, an estimate of the population average:

$$\bar{x} = \Sigma P_{\text{meas}}/n.$$

- USL Upper specification limit for a given P_T .
- LSL Lower specification limit for a given P_T .
- RH Water vapour pressure at a particular temperature expressed as a percentage of the saturation vapour pressure at the same temperature.

5 Requirements

5.1 General

Unless justified by the risk assessment, the following general requirements apply.

- a) The ADDD shall be designed so that, when operated in accordance with the instructions for use, it provides the emitted mass or dose as specified and verified by the ADDD manufacturer (see 5.4).
- b) The ADDD shall be designed so that the operator is aware that the ADDD has been actuated.
- c) The ADDD shall be designed to minimize the risk of inadvertent actuation.
- d) The performance of the combination of the ADDD and any accessory specified by the ADDD manufacturer shall comply with the device functionality profile and system verification test applicable to that combination. The manufacturer shall identify as part of the ADDD or ADDD system the specific accessories that are suitable for use.
- e) The ADDD shall be designed so that the operator can determine when the medication intended to be delivered is near completion and is near or has reached exhaustion.
- f) A prefilled ADDD with an actuation counter or content indicator shall not reset once the end of life is reached. A refillable ADDD with an integrated counter shall allow for resetting once the ADDD is replenished with medication.
- g) The manufacturer shall provide information to the operator to indicate when the ADDD needs to be replaced or has reached the end of its in-use life (see Annex A for rationale). This requirement also applies to all accessories necessary to meet the device functionality profile requirements.
- h) The design process shall include a provision of rationale for the selection of materials. In the selection of materials to be used in device manufacture, the first consideration should be fitness for purpose with regard to characteristics and properties, including chemical, toxicological, physical, electrical, morphological and mechanical attributes of the material.

To give assurance that the final product will perform as intended and be safe for human use, the programme shall include an appropriate biological evaluation in accordance with ISO 10993-1.

NOTE 1 ISO 10993-1 gives guidance on which parts of the ISO 10993 series are relevant to comply with.

- i) The ADDDs shall be designed to minimize:
 - ingress of foreign particles;
 - creation of particles from the ADDD itself (e.g. abrasion);
 - microbiological contamination.
- j) ADDDs and/or their components which by their design or intended purpose are required to be sterile, shall be designed so that they can be subjected to sterilization processes in accordance with ISO 17665-1, ISO 11135-1 or ISO 11137 or other validated sterilization process.

ISO 20072:2009(E)

- k) Software shall be designed based on a life cycle model in accordance with IEC 62304. The ADDD shall fulfil the applicable requirements of IEC 62304.
- l) ADDDs and/or their components, which by their design or intended purpose are required to be cleaned, disinfected or sterilized by the operator, shall be provided with adequate instructions for the operator to perform the cleaning, disinfection or sterilization. These methods shall be verified by the manufacturer as achieving their intended purpose.
- m) ADDDs with electrical components shall comply with IEC 60601-1, IEC 60601-1-2 and IEC 62366.
- n) If the ADDD contains an electronic alarm system, the ADDD shall comply with IEC 60601-1-8 and IEC 62366.
- o) For pre-filled and fixed-dose ADDDs the dose and number of actuations shall be clearly indicated on the ADDD.

NOTE 2 This could be accomplished by labelling.

- p) In the case of selected-dose ADDDs, the following shall be clearly indicated (see Annex A for rationale):
 - the magnitude and units (e.g. µg, ml, IU etc) for the selected dose;
 - that the selected dose is ready to be delivered.
- q) A selected-dose ADDD (see Annex A for rationale) shall be designed so that one of the following applies:
 - a dose cannot be set to a value greater than the medication that remains;
 - the ADDD does not allow delivery if the dose set is greater than the medication that remains;
 - the ADDD indicates the amount of medication delivered (i.e. portion of the set dose delivered);
 - the ADDD indicates the amount of medication NOT delivered (i.e. portion of the set dose yet to be delivered).
- r) The ADDD shall be designed such that the identity of the medication in pre-filled devices can be determined by the operator or that medication to be used with non-pre-filled ADDDs is clearly specified.

NOTE 3 This could be accomplished by labelling.

5.2 Risk assessment requirements

The manufacturer shall conduct a risk assessment, in accordance with ISO 14971, that will determine the parameters that shall then be included in the device functionality profile. The risk assessment shall also determine the appropriate statistical requirements for the system verification test. That risk assessment shall consider, at a minimum, all aspects of the intended use of the ADDD, as listed in ISO 14971:2007, Annex C.

5.3 Device functionality profile

There shall be established a device functionality profile (DFP) based on the outcome of the risk assessment in 5.2. The DFP shall consist of identified critical functions and design features, test methodology, tolerance limits and acceptance criteria (see Annex B).

5.4 System verification test

Once the DFP has been completed (and has been provided with acceptance criteria), a system verification test shall be performed on the ADDD. This comprises either emitted mass or dose testing, as determined from the risk assessment. This ADDD system verification test shall only be performed at standard atmosphere and

a nominal flow rate with either the placebo, the medication or a representative medication. If the ADDD is designed to operate over a range of dose sizes, the low, mid and high dose size shall be evaluated (see C.2).

5.5 Uncertainty of measurements and conformance with specification

Due to the nature of the statistical tolerance interval approach (6.4.2), random measurement error is automatically included in the standard deviation and a large measurement uncertainty will make it harder to pass the test.

Systematic measurement uncertainty (e.g. bias due to calibration error, instrumentation or other day-to-day variation) is not automatically included in the test and shall be considered when setting the parameter specifications and tolerances.

5.6 Test requirements

5.6.1 General

ADDs that have different operating temperatures and/or environmental requirements different from those specified in this International Standard shall be subjected to the relevant test at those acceptable operating conditions. These acceptable conditions shall be stated in the instructions for use.

5.6.2 ADDs subjected to standard, cool and hot atmospheres and after claimed lifetime testing

When tested in accordance with to 6.2.2:

- none of the ADDs shall have visible defects after being subjected to standard, cool and hot atmospheres;
- the ADDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to standard, cool and hot atmospheres;
- none of the ADDs shall have visible defects after being subjected to claimed lifetime testing;
- the ADDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to claimed lifetime testing.

ADDs designed for a single actuation shall be excluded from claimed lifetime testing.

5.6.3 ADDs subjected to heat storage atmosphere

When tested in accordance with 6.2.3:

- none of the ADDs shall have visible defects after being subjected to a heat storage atmosphere;
- the ADDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to a heat storage atmosphere.

5.6.4 ADDs subjected to cold storage atmosphere

When tested in accordance with 6.2.4:

- none of the ADDs shall have visible defects after being subjected to a cold storage atmosphere;
- the ADDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to a cold storage atmosphere.

5.6.5 ADDDs subjected to cyclical atmosphere

When tested in accordance with 6.2.5:

- none of the ADDDs shall have visible defects after being subjected to a cyclical atmosphere;
- the ADDDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to cyclical atmosphere.

5.6.6 ADDDs subjected to free fall

When tested in accordance with 6.2.6:

- none of the ADDDs shall have visible defects after being subjected to free fall;
- the ADDDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to free fall.

If, per the risk assessment, the conditions specified in 5.6 are not justified and more appropriate “worst-case” conditions are identified, test the ADDD according to these new conditions and document in the test report.

5.6.7 ADDDs subjected to vibration and shock

When tested in accordance with 6.2.7:

- none of the ADDDs shall have visible defects after being subjected to vibration and shock;
- the ADDDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to vibration and shock.

If, per the risk assessment, the conditions specified in 5.6 are not justified and more appropriate “worst-case” conditions are identified, the ADDD shall be tested according to these new conditions and document in the test report.

5.6.8 ADDDs with electrical components subjected to electromagnetic compatibility (EMC)

5.6.8.1 General

The requirements given in 5.6.8.2 and 5.6.8.3 are requirements substituting those specified in IEC 60601-1-2 as the latter standard covers requirements for electro-medical appliances in general only, and it does not specifically address ADDDs.

ADDDs without electrical components shall not be required to fulfil the requirements of this sub-clause.

If, per the risk assessment, the conditions specified in 5.6 are not justified and more appropriate “worst-case” conditions are identified, the ADDD shall be tested according to these new conditions and document in the test report.

NOTE The tests specified in 5.6.8.2 and 5.6.8.3 are based on the requirements given in the collateral standard IEC 60601-1-2. In that standard, EMC references are given to IEC 61000-4-1 and IEC 61000-4-2, Edition 2.1 and IEC 61000-4-3, Edition 3.

5.6.8.2 Electrostatic discharge

When tested in accordance with 6.2.8:

- none of the ADDDs shall have visible defects after being subjected to electrostatic discharge levels;
- the ADDDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to electrostatic discharge levels.

5.6.8.3 Radio frequency (RF) fields

When tested in accordance with 6.2.8:

- none of the ADDDs shall exhibit erroneous indications during the radio frequency sweep;
- none of the ADDDs shall have visible defects after being subjected to radio frequency fields;
- the ADDDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to radio frequency fields.

5.6.9 ADDDs subjected to sterilization

When tested in accordance with 6.2.9:

- none of the ADDDs shall have visible defects after being subjected to sterilization;
- the ADDDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to sterilization.

ADDDs that do not require sterilization shall not be required to fulfil the requirements of this sub-clause.

5.6.10 ADDDs subjected to cleaning and disinfection

When tested in accordance with 6.2.10:

- none of the ADDDs shall have visible defects after being subjected to cleaning and disinfection;
- the ADDDs shall have a device functionality profile within the limits specified by the manufacturer after being subjected to cleaning and disinfection.

The cleaning process specified in the instructions for use shall not have an adverse effect on the device functionality profile of the device.

ADDDs that do not require cleaning and disinfection shall not be required to fulfil the requirements of this sub-clause.

5.6.11 ADDDs subjected to system verification test

- none of the ADDDs shall have visible defects after being subjected to a system verification test;
- the ADDDs shall have an emitted mass or dose within the limits specified by the manufacturer after being subjected to a system verification test (see C.2 for guidance regarding the appropriate methods to evaluate aerosol measurements).

6 Test methods

6.1 General

To ensure that both inter-device and intra-device variability are adequately assessed, each ADDD shall provide only one data-set for each DFP parameter, P_T , being evaluated and for the system verification test.

For refillable ADDDs to satisfy test requirements defined in Clause 5, it is not necessary to perform test evaluations (device functionality profile and visual inspection) after each test procedure specified in 6.2.2 to 6.2.11. In such cases, the test evaluations shall be performed after the last test to which the ADDD has been subjected.

NOTE If this final evaluation produces a failure, the manufacturer might be unable to determine at which point in the testing series the failure occurred.

Unless otherwise specified, all tests and test evaluations shall be performed at standard atmosphere conditions (as defined in 6.3.2).

The ADDD shall be prepared in accordance with the instructions for use.

The ADDD shall be operated either manually or automatically, in a way that simulates operation by the end-user, as described in the instructions for use.

6.2 Test procedures

6.2.1 General

The purpose of these tests is to evaluate the ADDD device function when operated at the specified environmental conditions. For this reason testing should be performed at that environmental condition. However, where justified in order to be equivalent to the risk assessment (e.g. the time required to remove ADDD from the pre-conditioning environment and test is sufficiently short as to not impact the intent of the given requirement), testing may be performed at ambient environmental conditions.

Using the probability content levels shown in Table 1, the two-sided statistical tolerance interval (or one-sided statistical tolerance interval, as appropriate) for a given test (see 6.4.2) and P_T can be calculated.

The manufacturer shall select the appropriate number of ADDDs to test for the tests specified in 6.2.2 to 6.2.11 (denoted by n), recognizing that the target k value will increase as the sample size selected decreases.

The minimum test requirements to be evaluated are summarized in Table 2. If, per the risk analysis, flow rate has an effect on the parameter being tested, then that test shall be conducted at the upper and lower boundaries of the design specification flow rate range. Otherwise, the nominal flow rate shall be used.

6.2.2 ADDDs subjected to standard, cool and hot atmospheres and after claimed lifetime testing

Subject n new ADDDs to the standard atmosphere specified in 6.3.2 and evaluate the device functionality profile at these conditions in accordance with 6.4.2.

Subject the same ADDDs to the cool atmosphere specified in 6.3.3 and evaluate the device functionality profile at these conditions in accordance with 6.4.2.

Subject the same ADDDs to the hot atmosphere specified in 6.3.4 and evaluate the device functionality profile at these conditions in accordance with 6.4.2.

Determine the claimed lifetime of the ADDD.

Subject n ADDDs tested above to the claimed lifetime testing (simulate manual use in accordance with the instructions for use) until $1,5 \times$ the number of actuations of the claimed lifetime (in accordance with the manufacturer's product file) is reached.

If the ADDD is designed to stop working after a limited time or number of actuations (e.g. pre-filled multi-dose ADDD, refillable ADDD with non-replaceable batteries), the total number of actuations (less the number of actuations required for evaluation of the device functionality profile) shall be adopted for this test.

Visually inspect the ADDDs in accordance with 6.4.4.

Subject the same ADDDs above to the standard atmosphere specified in 6.3.2 and evaluate the device functionality profile in accordance with 6.4.2.

Table 1 — Minimum confidence and probability content requirements for data by test type

Test type (and minimum confidence)	Test type (and minimum probability content, p)	Examples of n , number of ADDs to test ^a	Corresponding two-sided target k for each n (from Annex D)	Corresponding one-sided target k for each n (calculated per ISO 16269-6)
DFP (with the exception of aerosol measurements) ^b In-use condition testing 0,95	In-use condition testing ($p = 0,975$)	60	2,670	2,384
		30	2,921	2,609
		25	3,015	2,691
		20	3,154	2,810
		15	3,386	3,005
DFP (with the exception of aerosol measurements) Extreme condition testing 0,95	Extreme condition testing ($p = 0,950$)	60	2,335	2,023
		30	2,555	2,220
		25	2,638	2,292
		20	2,760	2,397
		15	2,965	2,567
System verification test and DFP (aerosol measurements only) ^b	As determined by the risk assessment	As determined by the risk assessment	NA	NA

NOTE The sampling plans for inspection selected for this International Standard are intended to verify the design at a high confidence level. The sampling plan does not replace the more general manufacturing quality systems, including lot release, which appear in standards on quality systems, e.g. the ISO 9000 series or ISO 13485.

^a The numbers of ADDs, n , in Table 1, are provided for example only.

^b Aerosol measurements are those measuring the dose, emitted mass or any particle size measurements of the aerosol that is emitted.

Table 2 — Minimum DFP test requirements (with the exception of aerosol measurements ^a)

Test type	Confidence	Content P	Sub-clause	Descriptions	Refillable ADD	Pre-filled ADD
In-use condition testing	0,95	$(p = 0,975)$	5.6.2	Standard, cool, hot, lifetime, heat storage, cold storage	X	X
			5.6.3		X	X
			5.6.4		X	X
			5.6.4		X	X
Extreme condition testing	0,95	$(p = 0,950)$	5.6.5	Cyclical ^b	X	—
			5.6.6		X	X
			5.6.7	free fall	X	X
			5.6.8 ^c		X	X
			5.6.8 ^c	vibration, shock electrostatic	X	X
			5.6.9 ^d		X	X
5.6.10 ^e	RF fields sterilization cleaning	X	X			

NOTE "X" signifies a requirement and "—" signifies an exemption from the requirement.

^a ADDs that have different operating temperatures and/or environmental requirements from those specified in this International Standard shall be subjected to the relevant test at those acceptable temperatures. These acceptable conditions shall be stated in the instructions for use.

^b Prefilled ADDs shall be exempt from cyclical atmosphere testing.

^c ADDs without electronic components shall be exempt from electromagnetic compatibility testing.

^d ADDs that do not require sterilization shall be exempt from sterilization testing.

^e ADDs that do not require cleaning and disinfection shall be exempt from cleaning and disinfection testing.

6.2.3 ADDDs subjected to heat storage atmosphere

Subject n new ADDDs to the heat storage atmosphere specified in 6.3.5.

Visually inspect the ADDDs in accordance with 6.4.4.

Subject the ADDDs to the standard atmosphere specified in 6.3.2.

Evaluate the device functionality profile in accordance with 6.4.2.

6.2.4 ADDDs subjected to cold storage atmosphere

Subject n new ADDDs to the cold storage atmosphere specified in 6.3.6.

Visually inspect the ADDDs in accordance with 6.4.4.

Subject the ADDDs to the standard atmosphere specified in 6.3.2.

Evaluate the device functionality profile in accordance with 6.4.2.

6.2.5 ADDDs subjected to cyclical atmosphere

Subject n new ADDDs to the cyclical atmosphere specified in 6.3.7.

Visually inspect the ADDDs in accordance with 6.4.4.

Subject the ADDDs to the standard atmosphere specified in 6.3.2.

Evaluate the device functionality profile in accordance with 6.4.4.

6.2.6 ADDDs subjected to free fall

Prepare the ADDD by removing from the carton and remove any other secondary packaging. Perform the test:

- a) with the cap (e.g. mouthpiece cover) in position;
- b) with the cap removed.

The free fall test shall be performed using a free fall system as specified in IEC 60068-2-32, or other justified worst case conditions.

The test surface shall be smooth, hard, rigid and made of steel of 3 mm thickness backed by wood of between 10 mm and 19 mm thickness.

Subject n new ADDDs to the standard atmosphere specified in 6.3.2 and continue as described below.

Drop each ADDD three times by free fall in accordance with the conditions specified in IEC 60721-3-7 Class 7M3, on to the test surface, in a minimum of three substantially differing orientations, derived from the typical orientations for storage and use in consideration of the risk analysis and device development history. The ADDD shall be dropped in a non-turbulent way.

Visually inspect the ADDDs in accordance with 6.4.4.

Evaluate the device functionality profile in accordance with 6.4.2.

6.2.7 ADDDs subjected to vibration and shock

Prepare the ADDDs according to the instructions for use.

Subject n new ADDDs to the standard atmosphere specified in 6.3.2 and continue as described below.

Subject the ADDDs to vibration in accordance with the methods, procedures and equipment described in IEC 60068-2-64, or other justified worst case conditions.

Subject the ADDDs to the conditions specified in IEC 60721-3-7 Class 7M3.

The vibration time in each direction shall be 1 h.

Subject the ADDDs to the shock test in accordance with IEC 60068-2-27.

Subject the ADDDs to the conditions specified in IEC 60721-3-7 Class 7M3.

Visually inspect the ADDDs in accordance with 6.4.4.

Evaluate the device functionality profile in accordance with 6.4.2.

ADDs that cannot satisfy the requirements of vibration and shock testing in this International Standard shall be subjected to such testing at the acceptable conditions. Appropriate guidance as to the avoidance of excessive vibration shall be included in the instructions for use.

For intensive transportation of equipment over heavy surfaces, the Type I shock test should be over a number of 100 shocks positive and 100 negative.

NOTE 1 IEC 60068-2-64 describes the test equipment for the vibration test.

NOTE 2 For clarification: the test described above is applicable to electrical and non-electrical ADDDs (there are no other shock standards available for non-electrical ADDDs).

- IEC 60721-3-7 specifies requirements for portable ADDDs. Class 7M3 is selected because of its description of transportation of the ADDD;
- IEC 60068-2-27 describes the test equipment for the shock test;
- the shock response test Type I represents transport of the ADDD in its packaging;
- the shock response test Type II represents the ADDD in use (without packaging).

6.2.8 ADDDs with electrical components subjected to electromagnetic compatibility (EMC) testing

Subject n new ADDDs to the standard atmosphere specified in 6.3.2 and continue as described below.

Test the ADDDs for exposure to electrostatic discharge and radio frequency (RF) as follows.

Place n ADDDs with the primary packaging on a metal reference plane as specified in IEC 61000-4-2, or other justified worst case conditions.

Apply contact discharges of (± 2 , ± 4 and ± 8) kV to conductive accessible parts and coupling planes.

Apply air discharges of (± 8 , ± 10 , ± 12 and ± 15) kV to non-conductive accessible parts.

The number of discharges at each level and polarity shall be 10 with a time interval of 1 s between the individual discharges.

Test the same ADDDs in accordance with IEC 61000-4-3 [transversal electromagnetic mode (TEM) cells or gigahertz transverse electromagnetic (GTEM) cells may be used as described in Annex D of that standard].

As stated in IEC 61000-4-3, the requirement for field uniformity shall be fulfilled in the area corresponding to the unit under test.

Test the same ADDDs at the 10 V/m level (unmodulated carrier) in the frequency range of (26 to 2 000) MHz.

The test signal shall be AM modulated with 1 kHz sinusoidal and to a modulation depth of 80 %.

Perform the test in each of the three axes of the ADDD.

Visually inspect the ADDDs in accordance with 6.4.4.

Evaluate the device functionality profile in accordance with 6.4.2.

6.2.9 ADDDs subjected to sterilization

Subject *n* new ADDDs to the specified sterilization procedure described in the product labelling.

Visually inspect the ADDDs in accordance with 6.4.4.

Subject the ADDDs to the standard atmosphere specified in 6.3.2.

Evaluate the device functionality profile in accordance with 6.4.2.

6.2.10 ADDDs subjected to cleaning and disinfection

Subject *n* new ADDDs to the specified cleaning and disinfection procedure described in the instructions for use.

Visually inspect the ADDDs in accordance with 6.4.4.

Subject the ADDDs to the standard atmosphere specified in 6.3.2.

Evaluate the device functionality profile in accordance with 6.4.2.

6.2.11 ADDDs subjected to system verification test

Subject *n* new ADDDs to the standard atmosphere specified in 6.3.2.

Evaluate the emitted mass or dose in a manner consistent with the instructions for use.

See Annex C.2 for guidance regarding the appropriate methods to evaluate aerosol measurements.

6.3 Test conditions

6.3.1 General

Unless otherwise specified, test measurements shall be performed at standard atmospheric conditions as specified in 6.3.2. A rationale for the environmental and mechanical conditions described herein can be found in C.1.

6.3.2 Standard atmosphere

Standard atmospheric conditions shall be defined as:

- temperature: $(25 \pm 2) ^\circ\text{C}$;
- relative humidity: $(60 \pm 5) \% \text{RH}$.

The ADDDs are subjected to storage for at least 4 h in this atmosphere.

6.3.3 Cool atmosphere

The ADDDs are placed in a test chamber for at least 4 h in the following cool atmosphere:

- temperature: $(5 \pm 3) ^\circ\text{C}$;
- relative humidity: ambient RH.

6.3.4 Hot atmosphere

The ADDDs are placed in a test chamber for at least 4 h in the following hot atmosphere:

- temperature: $(40 \pm 2) ^\circ\text{C}/(75 \pm 5) \%$ according to ICH;
- relative humidity: not more than 25 % RH.

6.3.5 Heat storage atmosphere

The ADDDs are placed in a test chamber for at least 96 h in the following dry heat atmosphere:

- temperature: $(50 \pm 2) ^\circ\text{C}$;
- relative humidity: ambient RH.

6.3.6 Cold storage atmosphere

The ADDDs are placed in a test chamber for at least 96 h in the following cold atmosphere:

- temperature: $(-20 \pm 5) ^\circ\text{C}$.

6.3.7 Cyclical atmosphere

The ADDDs are placed in a test chamber. Conditioning in accordance with IEC 60068-2-30 is carried out as follows:

- variant 1 (see IEC 60068-2-30:2005, Figure 2a);
- upper temperature: $(55 \pm 2) ^\circ\text{C}$;
- 6 cycles.

NOTE The relevant clauses of IEC 60068-2-30:2005 are: Clause 4: Testing chamber, Clause 7: Conditioning and Clause 9: Recovery.

6.4 Test evaluations

6.4.1 Test substance

For aerosol measurements, the substance to be tested in evaluating the device functionality profile (if required by the risk assessment) and the system verification test shall be either the medication, a representative medication or a placebo that has appropriate physical and chemical properties representative of the medication that will be used in the marketed ADDD. If a representative medication or placebo for the medication is used, it shall be supported by the risk assessment and may require bridging studies to demonstrate suitability.

6.4.2 Device functionality profile

With the exception of aerosol measurements, the device functionality profile shall be evaluated by selecting and testing a number of ADDDs. Assuming that the test results are normally distributed and that each measurement is independent, the following method enables test results to be used as the basis for determining a statistical tolerance interval for the relevant dose selections, i.e. an interval such that there is a fixed probability (confidence level) that the interval will contain at least a proportion (p , probability content) of the true population from which the sample is taken. The statistical tolerance interval is two-sided, and the limits of the interval are called “statistical tolerance limits” or “natural limits of the process”. To pass the device functionality profile requirement, there shall be a 95 % confidence that at least p of all values will fall between the previously determined tolerance limits (also referred to as the upper and lower specification limits) for the relevant P_T .

The two-sided statistical tolerance interval is calculated using the average, \bar{x} , plus or minus the standard deviation, s , multiplied by a tolerance limit factor, k :

$$\bar{x} \pm k \times s$$

where \bar{x} is the average of the sample values.

The factor, k , is determined based upon the confidence level (95 %), probability content, p , and the number of measurements, n , taken for a given P_T . Annex D contains a comprehensive table of two-sided tolerance limit factors for the 95 % confidence level.

An ADDD population satisfies the requirements when, for a given P_T , the following expressions are fulfilled:

$$\bar{x} + (k \times s) \leq \text{USL};$$

$$\bar{x} - (k \times s) \geq \text{LSL}.$$

NOTE 1 Using ISO 16269-6, a similar set of relationships can be applied for one-sided statistical tolerance intervals. It also addresses situations when the data is not normally distributed. ISO 16269-6:2005, Annex E, lists the tolerance limit factors for the construction of two-sided statistical tolerance intervals when the true population mean and standard deviation are not known.

NOTE 2 For aerosol measurements identified as part of the DFP, refer to C.2.

NOTE 3 The above acceptance criterion is simple to evaluate. A more elaborate and precise acceptance criterion is provided in Annex E. Either of the criteria may be used in the performance evaluation.

6.4.3 System verification test

While no specific methodology is defined as part of this International Standard, C.2 provides some perspective and guidance relative to evaluating the emitted mass or dose.

6.4.4 Visual inspection

Evaluate and confirm the functional performance (e.g. stored data, settings, dose or indications) of each ADDD that has electronic components.

Markings on each ADDD (e.g. words, characters, numbers, symbols, quantity/volume scales, grid lines, and index marks) shall remain visible and easily legible by normal vision, or vision corrected to normal, at environmental lighting conditions of 215 (± 20) lx.

Inspect each ADDD for significant defects under normal (corrected, if needed) vision. Defects in electronic parts leading to non-functioning are permitted if the non-functioning is obvious to the operator.

The inspection shall in particular include checking for significant defects such as:

- displaced parts;
- markings no longer in place, visible and clearly legible by normal vision;
- cracks in the body and/or component of the ADDD that might impact the safe functioning of the ADDD;
- compromised assembly bonds, joints and alignments.

7 Test report

The test report shall be maintained in accordance with records needed to provide evidence that the realization processes and resulting ADDD meet the requirements. A summary of results from testing in accordance with Table 1 shall be described in the report.

8 Information supplied by the manufacturer

8.1 General

The ADDD shall be accompanied by instructions for use, taking into account the training and knowledge of the operators. Instructions for use shall be included in/on the secondary packaging container.

8.2 Marking

8.2.1 Marking on the ADDD

Any marking on the ADDD that is essential for the identification and safe use of the device shall be legible and indelible after being subjected to the test requirements specified in 5.6. Legibility shall be assessed using normal or corrected-to-normal vision at an environmental lighting condition of (215 ± 20) lx.

The marking on the ADDD shall contain at least the following:

- a) the product manufacturer;

NOTE A trademark or logo can be sufficient to identify the manufacturer.

- b) the product name;
- c) the lot number or the serial number;
- d) if the ADDD contains an integral supply of medication, information on the medication delivered, the label claim, the labelled number of actuations and the expiry date in the format expressing at least year and month (e.g. 2008-12);
- e) if the ADDD or any component is provided sterile, a statement or symbol, in accordance with ISO 15223-1, indicating the method of sterilization.

The manufacturer shall mark accessories so that they are clearly identified. The marking on accessories shall contain at least a), b) and c).

8.2.2 Marking on the secondary packaging container

Any marking on the secondary packaging container that is essential for the safe use of the ADDD shall be legible. Legibility shall be assessed using normal or corrected-to-normal vision at an environmental lighting condition of (215 ± 20) lx.

The marking on the secondary packaging container shall contain at least the following:

- a) the product manufacturer;
- b) the product name;
- c) the content of the primary packaging container;
- d) whether the ADDD contains an integral supply of medication or whether the primary packaging container of the ADDD contains a supply of medication, information on the medication delivered, the label claim, the labelled number of actuations and the expiry date in the format expressing at least year and month (e.g. 2008-12);
- e) the lot number or the serial number; on ADDDs not having an integral supply of medication, this requirement is determined by the risk assessment;
- f) any special storage and/or handling conditions.

8.3 Instructions for use

The instructions for use shall contain at least the following information:

- a) the information required in 8.2.1 except that the information regarding expiry date, lot number or serial number can be omitted;
- b) if no expiry date is specified for a refillable ADDD, the instructions shall indicate for how long after first use or for how many actuations it is intended to be used before being discarded;
- c) information on how the ADDD is to be correctly used, using graphics when appropriate:
 - 1) how it should be removed from the package, if this is relevant;
 - 2) any preparatory actions for first-time use (e.g. battery loading, function testing) or instructions for assembly or for use with an accessory, as appropriate;
 - 3) in the case of an ADDD that does not contain an integral supply of medication, how it is assembled and/or loaded with a dose of medication;
 - 4) appropriate actions that need to be performed prior to actuation (e.g. shaking, priming, device orientation, selecting the dose, etc.);
 - 5) instructions on how the operator is to actuate and to inhale (e.g. exhalation, actuation, inspiratory effort, duration, breath holding, repetition of inhalation);
 - 6) instructions on how the operator is to prepare the ADDD for storage or non-use after actuation;
 - 7) instructions on how the ADDD is to be re-used, cleaned, disinfected or sterilized as appropriate, if it is refillable;
 - 8) instructions on how to dispose of the ADDD or parts thereof at the end of their intended life;

- d) information on warnings or precautions to be taken:
 - 1) a statement that if it appears to the operator that the ADDD is not functioning correctly, to seek advice from a healthcare professional;
 - 2) how the operator can synchronize inspiratory effort with actuation, if this is needed;
 - 3) in the case of a selected-dose ADDD, that it shall only be used by operators able to select the correct dose;
 - 4) in the case of a selected-dose ADDD, how the ADDD operates when the amount of medication available is less than the dose the operator intends to select;
- e) in the case of a selected-dose ADDD, instructions on the dose-setting method and the dose-setting range;
- f) if acceptable storage temperatures are other than those specified in 6.3 (+40 °C and –20 °C) the acceptable temperature range for storage of the ADDD without medication;
- g) any special storage requirements;
- h) type of replaceable batteries and their number, if used, and instructions to recycle the used batteries;
- i) a description of any special features;
- j) details advising the operator on any contra-indications and any precautions to be taken, as appropriate; these details should cover precautions to be taken in the event of breakage or changes in the performance of the ADDD;
- k) identification of accessories that are suitable for use, where known.

Annex A (informative)

Rationale for requirements

A.1 Introduction

This annex contains rationale statements for some of the requirements of this International Standard. It is included to provide additional insight into the reasoning that led to the requirements and recommendations that have been incorporated in this International Standard. It is considered that knowledge of the reasons for the requirements will not only facilitate the proper application of this International Standard, but will expedite any subsequent revisions.

The scope of this International Standard covers a diversity of ADDDs according to their design, construction and operation: passive *versus* active devices, devices containing a supply of medication *versus* unit doses, refillable *versus* non-refillable, fixed dose *versus* selected dose, etc.

The requirements of this International Standard were developed taking into account currently marketed ADDDs as well as ADDDs that are still under development at the time of writing. As the technology is rapidly evolving, this International Standard hopes to bridge the old and the new, without hindering the former or restricting progress in the latter. Consequently, this informative annex is provided to allow the reader to understand the thinking of the authors.

The committee is aware that certain currently marketed devices are not able to meet some of the requirements. However, since this document is designed to encourage future development and progress, the committee believes Clause 5 contains requirements that will advance patient safety.

For a given manufacturer, existing ADDDs and those currently under development may not fulfil some of the requirements. However, manufacturers should comply with this International Standard when improving the functional design of marketed ADDDs or when developing new ADDDs to obtain an even higher level of quality.

The numbering of the following rationale corresponds to the numbering of the clauses in the main text. The numbering is, therefore, not consecutive.

A.2 Rationale for requirements (5.1)

5.1 a): Concerning the delivery of the emitted mass, the objective for new ADDDs should be to ensure that an actuation has occurred from the ADDD. If the patient is not able to verify this, then the design of new ADDDs should ensure that objective by providing indicative means with the device.

5.1 b): This subclause concerns the awareness of the patient that the ADDD has been actuated. Feedback that actuation has occurred should provide positive confirmation to the operator and not just rely on the correct use of the device according to the instructions.

5.1 g): The information concerning the number of actuations or amount of medication left inside the device is essential for all ADDDs where that amount of medication is not immediately visible or measurable by the operator.

For ADDDs that can be refilled and thus re-used, the focus is on establishing how many times or for how long the ADDD can be used before being replaced.

5.1 i): This requirement is intended to prevent foreign materials entering the aerosol transport pathway of the ADDD or interfering with the mechanism that would prevent usual function of the ADDD, and prevent inhalation of foreign material (discrete objects that are not part of the ADDD or its medication).

5.1 p): This subclause only applies to ADDDs that have, or allow input from, a reservoir that contains a labelled volume of medication from which the operator can select a dose.

The device must be able to indicate the magnitude and unit of the dose the operator can select. These units must be the same as the units in which the medicine is labelled.

For example, an insulin medication ADDD which has a reservoir (fixed or replaceable) which contains 100 IU of insulin when full, must display both the magnitude and units (e.g. 50 IU) that the operator has selected.

A morphine medication or a fentanyl medication ADDD which has a reservoir (fixed or replaceable) which contains 100 µg of fentanyl or 100 mg of morphine when full, must display both the magnitude and units (e.g. 20 µg of fentanyl or 30 mg of morphine) the operator has selected.

5.1 q): This subclause only applies to ADDDs that have, or allow input from, a reservoir that contains a labelled volume of API from which the operator can select a dose.

The device must inform the operator if the selected dose is larger than the API remaining in the reservoir. This can be done either prospectively or retroactively in two ways:

- Prospectively (before actuation):
 - a selected dose cannot be set at a value that is greater than the dose that is available in the reservoir in the ADDD or
 - the ADDD does not allow any dose delivery if the selected amount exceeds the dose that is available in the reservoir in the ADDD.
- Retrospectively (after actuation):
 - the ADDD indicates the amount of the selected dose actually delivered or
 - indicates the amount of the selected dose not delivered.

For example, an insulin ADDD that has a reservoir (fixed or replaceable) which contains 10 IU of insulin would do the following if the operator requested a 15 IU dose:

- the ADDD would display/indicate a 10 IU dose, only allowing selection of doses at 10 IU or less;
- the ADDD would display 15 IU but not allow actuation unless the dose requested was changed to 10 IU or less;
- the ADDD would allow and display the 15 IU dose before actuation, but would indicate that 10 IU had been delivered after actuation;
- the ADDD would allow and display the 15 IU dose before actuation but would indicate that 5 IU had NOT been delivered after actuation.

Annex B **(informative)**

Further guidance and clarification of the device functionality profile

This annex provides further guidance and clarification about the device functionality profile (DFP). This design verification standard applies to the functionality of the device (its components and design) and robustness of ADDD devices. The focus of this DFP is the design function of the ADDD. Once the functionality testing of the ADDD has been completed, verification testing of the delivery performance of the whole ADDD system is required at standard conditions.

ADDDs comprise many different configurations (e.g. pMDIs, DPIs, nasal delivery systems etc.) and there are many different designs within each of these configurations. Further, this array of ADDDs deliver APIs that may be topical (local) or systemic in their site of action with many formulation variations, dose strengths and therapeutic indices. As such the criteria used to demonstrate device functionality may require a number of different test methods that will depend on the ADDD being considered. The device functionality profile including the specific tests for a particular ADDD should be identified through the risk assessment process which will include consideration of the components and materials of the ADDD and their interaction with the medication and interface with the end user.

Some examples of functionality tests are provided here and may include dimensional analysis, mechanical function, actuation etc., see Figure B.1.

Based on the selection of the tests the appropriate protocols may be developed and statistics be applied to demonstrate robust and safe operation of the ADDD after exposure to the storage conditions given in this International Standard.




Figure B.1 — Examples of functionality tests

Annex C (informative)

Rationale for test methods

C.1 Rationale for preconditioning and test conditions (subclauses 6.2 and 6.3)

6.2.6 Free fall

This preconditioning is to simulate accidental dropping of the ADDD by the operator. It is done in compliance with an established IEC standard. The height at which the device can be dropped has been differentiated to adjust the difference in the force of impact caused by the increase in mass or weight. However, manufacturers should use their risk assessments to assure that the height chosen is appropriate for their devices.

6.2.7 Vibration and shock

This preconditioning is to simulate the transport of the ADDD by the operator during normal travel with any caps and/or specified or supplied protective carrying cases. It may also be done without protective materials. It is not a substitute for shipping tests of the final ADDD in its packaging.

6.2.8 EMC

This is a standardized preconditioning scheme for electronic ADDDs to simulate exposure to electromagnetic radiation that may be in the operator environment, including mobile telephones. This is a standard IEC electrical challenge.

6.2.9 Sterilization

This is for ADDDs that will be provided sterile and is included to ensure that the device performs as designed after exposure to the validated sterilization cycle. If the device can be sterilized multiple times, this must be included in the preconditioning.

6.2.10 Cleaning and disinfection

This preconditioning is to simulate the effects of the recommended cleaning and disinfection recommended by the manufacturer so that it can be determined not to adversely affect the performance of the device.

6.2.11 System verification test

Once the ADDD has met the device functionality profile a final holistic system evaluation is conducted at standard atmosphere and nominal flow rate as a simple bridge between the device design and the patient interface; this includes one aerosol measurement per ADDD to confirm the ADDD system functions. If the ADDD is designed to operate over a range of dose sizes, the low, median and high dose size should be evaluated.

6.3.2 Standard atmosphere

The standard atmosphere is the condition at which the testing is performed for all tests except the cool atmosphere and hot atmosphere tests in 6.3.3 and 6.3.4. This environment represents the median or "room temperature" of the labelled use temperature range. Requiring the test samples to remain at specified atmospheres for a minimum of 4 h is to assure equilibration to ambient environmental conditions before testing.

6.3.3 Cool atmosphere

This environment shall represent the low extreme of the labelled¹⁾ use temperature range. The entire ADDD system²⁾ is preconditioned for a minimum of 4 h and tested at this temperature to represent the minimum temperature at which the ADDD is to be used by the patient. The RH is not specified at low temps because the maximum moisture content of the air at 5 °C is about 7 × lower than at 30 °C. The RH is therefore not seen as critical.

6.3.4 Hot atmosphere

This environment shall represent the high extreme of the labelled²⁾ use temperature range. The entire ADDD system is to be preconditioned for a minimum of 4 h and tested at this temperature to represent the maximum temperature at which the ADDD is to be used by the patient.

6.3.5 Heat storage atmosphere

This environment shall represent the high extreme of the labelled²⁾ shipping and storage temperature range. The entire ADDD system is to be preconditioned at this temperature and then tested in the standard atmosphere to represent the high excursion during shipping and storage.

6.3.6 Cold storage temperature

This environment shall represent the low extreme of the labelled²⁾ shipping and storage temperature range. The entire ADDD system is to be preconditioned at this temperature and tested in the standard atmosphere to represent the high excursion during shipping and storage.

6.3.7 Cyclical atmosphere

This extreme environmental conditioning is adapted from an IEC electro-mechanical standard to determine the effects on function of extreme temperature changes which stress component integrity and mechanical and physical interfaces and interactions. The conditions and temperatures are as specified in this International Standard. The lower elevated temperature in the IEC standard has been chosen as more appropriate for the ADDDs.

C.2 Aerosol measurements (subclauses 6.4.2 and 6.4.3)

Emitted mass and, when applicable, the particle size distribution can be assessed by a variety of methods described in the literature. Most commonly it is foreseen that methods applied in the development of ADDDs are the ones equivalent to those accepted by regulatory authorities. These can be as or derived from the test methods described in international Pharmacopeias. There are a number of active Pharmacopeias used today and the appropriate choice of test method depends on the intended place of marketing of the ADDD.

The Pharmacopeias describe the test methods and the parameters obtained as well as the calculations needed for evaluating the aerosol performance of the ADDD. This International Standard only refers to the use of the described test methods. Calculations on the data obtained are covered by this International Standard.

NOTE The statistical evaluation mainly refers to emitted mass. Note also the Pharmacopeial methods determine the API, not emitted mass.

1) This International Standard allows for use of other less severe conditions as long as these are clearly represented in the labelling. The manufacturer can also elect to test at more extreme conditions.

2) The test samples must be preconditioned and tested in the configuration provided to the customer. If the ADDD is provided pre-filled with the medication, then the test samples must be preconditioned and tested with pre-filled medication or placebo.

Established and recommended methods for the laboratory testing of ADDDs for dose, emitted mass and (aerodynamic) particle size distribution measurement (particle sizing) are available in both European and US Pharmacopeias (see Bibliography). The dose collection apparatus for either pressurized metered dose inhalers or dry powder inhalers (Ph.Eur and US Pharmacopeia) are appropriate for the determination of dose and emitted mass. The testing conditions, especially flow rate, should also be determined as described in the pharmacopeia and the ADDD operated as per the in-use instructions. It is recognised that, for some ADDDs with or without their configured accessories, these apparatus have to be modified to permit interfacing of the device and collection apparatus. A multi-stage cascade impactor chosen from the options provided in either pharmacopeia is appropriate for particle size measurements. These methods were developed for the evaluation of ADDDs without a spacer or holding chamber. The number of stages and which ones should be used need to be determined based up on the aerosol size distribution characteristics and specified within the risk assessment.

However, they may be adapted for the evaluation of these add-on devices where required. Methods described in a standard developed specifically for these spacer and holding chamber devices (CAN/CSA/Z264.1-02^[13]) are appropriate where it is necessary to evaluate the device functionality profile of the ADDD with this accessory requiring a delay following inhaler actuation.

In all cases the methodology must be validated for the ADDD system under test, to suitable standards.

The methods described in these source documents were developed for in-use testing and might require adaptation (e.g. the use of a climate-controlled enclosure) for application to extreme condition testing.

Alternate methods (e.g. the use of laser diffractometry in place of cascade impaction for particle sizing) may be used for ADDD aerosol measurements, where validated.

Annex D (informative)

Two-sided tolerance limit factors (k)

Table D.1 — Two-sided tolerance limit factors

n	Confidence = 95 %						
	$p = 0,750$	$p = 0,900$	$p = 0,950$	$p = 0,975$	$p = 0,990$	$p = 0,995$	$p = 0,999$
2	22,383	31,092	36,519	41,308	46,944	50,813	58,844
3	5,937	8,306	9,789	11,101	12,647	13,710	15,920
4	3,818	5,368	6,341	7,203	8,221	8,921	10,377
5	3,041	4,291	5,077	5,774	6,598	7,165	8,345
6	2,638	3,733	4,422	5,034	5,758	6,256	7,294
7	2,391	3,390	4,020	4,579	5,241	5,697	6,647
8	2,223	3,156	3,746	4,269	4,889	5,316	6,206
9	2,101	2,986	3,546	4,044	4,633	5,039	5,885
10	2,008	2,856	3,393	3,871	4,437	4,827	5,640
11	1,934	2,754	3,273	3,735	4,282	4,659	5,446
12	1,874	2,670	3,175	3,624	4,156	4,522	5,287
13	1,825	2,601	3,093	3,531	4,051	4,409	5,156
14	1,783	2,542	3,024	3,453	3,962	4,312	5,044
15	1,747	2,492	2,965	3,386	3,885	4,230	4,949
16	1,716	2,449	2,913	3,328	3,819	4,158	4,865
17	1,689	2,410	2,868	3,277	3,761	4,095	4,792
18	1,665	2,376	2,828	3,231	3,709	4,039	4,727
19	1,643	2,346	2,793	3,191	3,663	3,988	4,669
20	1,624	2,319	2,760	3,154	3,621	3,943	4,616
21	1,607	2,294	2,731	3,121	3,583	3,903	4,569
22	1,591	2,272	2,705	3,091	3,549	3,865	4,526
23	1,576	2,251	2,681	3,063	3,518	3,831	4,486
24	1,563	2,232	2,658	3,038	3,489	3,800	4,450
25	1,551	2,215	2,638	3,015	3,462	3,771	4,415
26	1,539	2,199	2,619	2,993	3,437	3,744	4,385
27	1,529	2,184	2,601	2,973	3,415	3,720	4,356
28	1,519	2,170	2,585	2,954	3,393	3,696	4,330
29	1,510	2,157	2,569	2,937	3,373	3,675	4,304
30	1,501	2,145	2,555	2,921	3,355	3,654	4,281

Table D.1 (continued)

<i>n</i>	Confidence = 95 %						
	<i>p</i> = 0,750	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995	<i>p</i> = 0,999
31	1,493	2,134	2,541	2,905	3,337	3,635	4,259
32	1,486	2,123	2,529	2,891	3,320	3,617	4,238
33	1,478	2,113	2,517	2,877	3,305	3,600	4,218
34	1,472	2,103	2,505	2,864	3,290	3,584	4,199
35	1,465	2,094	2,495	2,852	3,276	3,569	4,182
36	1,459	2,086	2,484	2,840	3,263	3,555	4,165
37	1,454	2,077	2,475	2,829	3,250	3,541	4,149
38	1,448	2,070	2,466	2,819	3,238	3,528	4,134
39	1,443	2,062	2,457	2,809	3,227	3,516	4,119
40	1,438	2,055	2,448	2,799	3,216	3,504	4,105
41	1,433	2,049	2,440	2,790	3,205	3,492	4,092
42	1,429	2,042	2,433	2,781	3,196	3,482	4,080
43	1,424	2,036	2,425	2,773	3,186	3,471	4,068
44	1,420	2,030	2,418	2,765	3,177	3,461	4,056
45	1,416	2,024	2,412	2,757	3,168	3,452	4,045
46	1,412	2,019	2,405	2,750	3,160	3,443	4,034
47	1,409	2,014	2,399	2,743	3,151	3,434	4,024
48	1,405	2,009	2,393	2,736	3,144	3,425	4,014
49	1,402	2,004	2,387	2,729	3,136	3,417	4,004
50	1,398	1,999	2,382	2,723	3,129	3,409	3,995
51	1,395	1,994	2,376	2,717	3,122	3,401	3,986
52	1,392	1,990	2,371	2,711	3,115	3,394	3,978
53	1,389	1,986	2,366	2,705	3,108	3,387	3,969
54	1,386	1,982	2,361	2,700	3,102	3,380	3,961
55	1,383	1,978	2,356	2,694	3,096	3,373	3,953
56	1,381	1,974	2,352	2,689	3,090	3,367	3,946
57	1,378	1,970	2,347	2,684	3,084	3,361	3,939
58	1,376	1,967	2,343	2,679	3,079	3,355	3,932
59	1,373	1,963	2,339	2,675	3,073	3,349	3,925
60	1,371	1,960	2,335	2,670	3,068	3,343	3,918
61	1,369	1,957	2,331	2,666	3,063	3,338	3,912
62	1,366	1,953	2,327	2,661	3,058	3,332	3,905
63	1,364	1,950	2,324	2,657	3,053	3,327	3,899
64	1,362	1,947	2,320	2,653	3,048	3,322	3,893

Table D.1 (continued)

<i>n</i>	Confidence = 95 %						
	<i>p</i> = 0,750	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995	<i>p</i> = 0,999
65	1,360	1,944	2,317	2,649	3,044	3,317	3,887
66	1,358	1,941	2,313	2,645	3,039	3,312	3,882
67	1,356	1,939	2,310	2,641	3,035	3,307	3,876
68	1,354	1,936	2,307	2,638	3,031	3,303	3,871
69	1,352	1,933	2,304	2,634	3,027	3,298	3,866
70	1,350	1,931	2,300	2,631	3,023	3,294	3,861
71	1,349	1,928	2,297	2,627	3,019	3,290	3,856
72	1,347	1,926	2,295	2,624	3,015	3,285	3,851
73	1,345	1,923	2,292	2,621	3,011	3,281	3,846
74	1,344	1,921	2,289	2,617	3,008	3,277	3,841
75	1,342	1,919	2,286	2,614	3,004	3,274	3,837
76	1,341	1,917	2,284	2,611	3,001	3,270	3,832
77	1,339	1,914	2,281	2,608	2,997	3,266	3,828
78	1,337	1,912	2,278	2,605	2,994	3,262	3,824
79	1,336	1,910	2,276	2,603	2,991	3,259	3,820
80	1,335	1,908	2,274	2,600	2,988	3,255	3,816
81	1,333	1,906	2,271	2,597	2,984	3,252	3,812
82	1,332	1,904	2,269	2,594	2,981	3,249	3,808
83	1,330	1,902	2,267	2,592	2,978	3,246	3,804
84	1,329	1,900	2,264	2,589	2,975	3,242	3,800
85	1,328	1,899	2,262	2,587	2,973	3,239	3,797
86	1,327	1,897	2,260	2,584	2,970	3,236	3,793
87	1,325	1,895	2,258	2,582	2,967	3,233	3,790
88	1,324	1,893	2,256	2,580	2,964	3,230	3,786
89	1,323	1,892	2,254	2,577	2,962	3,227	3,783
90	1,322	1,890	2,252	2,575	2,959	3,225	3,780
91	1,321	1,888	2,250	2,573	2,957	3,222	3,776
92	1,320	1,887	2,248	2,571	2,954	3,219	3,773
93	1,318	1,885	2,246	2,569	2,952	3,216	3,770
94	1,317	1,884	2,244	2,566	2,949	3,214	3,767
95	1,316	1,882	2,242	2,564	2,947	3,211	3,764
96	1,315	1,881	2,241	2,562	2,944	3,209	3,761
97	1,314	1,879	2,239	2,560	2,942	3,206	3,758
98	1,313	1,878	2,237	2,558	2,940	3,204	3,755
99	1,312	1,876	2,236	2,556	2,938	3,201	3,752

Table D.1 (continued)

<i>n</i>	Confidence = 95 %						
	<i>p</i> = 0,750	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995	<i>p</i> = 0,999
100	1,311	1,875	2,234	2,555	2,936	3,199	3,750
102	1,309	1,872	2,231	2,551	2,931	3,194	3,744
104	1,308	1,869	2,228	2,547	2,927	3,190	3,739
106	1,306	1,867	2,225	2,544	2,923	3,186	3,734
108	1,304	1,864	2,222	2,541	2,919	3,181	3,729
110	1,302	1,862	2,219	2,537	2,916	3,177	3,724
112	1,301	1,860	2,216	2,534	2,912	3,173	3,720
114	1,299	1,858	2,213	2,531	2,909	3,170	3,715
116	1,298	1,855	2,211	2,528	2,905	3,166	3,711
118	1,296	1,853	2,208	2,525	2,902	3,162	3,707
120	1,295	1,851	2,206	2,522	2,899	3,159	3,703
122	1,293	1,849	2,203	2,520	2,896	3,155	3,699
124	1,292	1,847	2,201	2,517	2,893	3,152	3,695
126	1,291	1,845	2,199	2,514	2,890	3,149	3,691
128	1,289	1,843	2,197	2,512	2,887	3,146	3,687
130	1,288	1,842	2,194	2,510	2,884	3,143	3,684
132	1,287	1,840	2,192	2,507	2,881	3,140	3,680
134	1,286	1,838	2,190	2,505	2,878	3,137	3,677
136	1,284	1,837	2,188	2,503	2,876	3,134	3,674
138	1,283	1,835	2,186	2,500	2,873	3,131	3,670
140	1,282	1,833	2,185	2,498	2,871	3,128	3,667
142	1,281	1,832	2,183	2,496	2,868	3,126	3,664
144	1,280	1,830	2,181	2,494	2,866	3,123	3,661
146	1,279	1,829	2,179	2,492	2,864	3,121	3,658
148	1,278	1,827	2,177	2,490	2,861	3,118	3,655
150	1,277	1,826	2,176	2,488	2,859	3,116	3,652
152	1,276	1,825	2,174	2,486	2,857	3,114	3,650
154	1,275	1,823	2,172	2,484	2,855	3,111	3,647
156	1,274	1,822	2,171	2,483	2,853	3,109	3,644
158	1,273	1,821	2,169	2,481	2,851	3,107	3,642
160	1,272	1,819	2,168	2,479	2,849	3,105	3,639
162	1,272	1,818	2,166	2,477	2,847	3,102	3,637
164	1,271	1,817	2,165	2,476	2,845	3,100	3,634
166	1,270	1,816	2,163	2,474	2,843	3,098	3,632
168	1,269	1,815	2,162	2,473	2,841	3,096	3,630

Table D.1 (continued)

<i>n</i>	Confidence = 95 %						
	<i>p</i> = 0,750	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995	<i>p</i> = 0,999
170	1,268	1,813	2,161	2,471	2,840	3,094	3,627
172	1,267	1,812	2,159	2,469	2,838	3,092	3,625
174	1,267	1,811	2,158	2,468	2,836	3,091	3,623
176	1,266	1,810	2,157	2,466	2,834	3,089	3,621
178	1,265	1,809	2,155	2,465	2,833	3,087	3,619
180	1,264	1,808	2,154	2,464	2,831	3,085	3,616
185	1,263	1,805	2,151	2,460	2,827	3,081	3,611
190	1,261	1,803	2,148	2,457	2,823	3,077	3,607
195	1,259	1,801	2,146	2,454	2,820	3,073	3,602
200	1,258	1,798	2,143	2,451	2,816	3,069	3,598
205	1,256	1,796	2,140	2,448	2,813	3,065	3,593
210	1,255	1,794	2,138	2,445	2,810	3,062	3,589
215	1,253	1,792	2,136	2,442	2,807	3,059	3,585
220	1,252	1,790	2,133	2,440	2,804	3,055	3,581
225	1,251	1,789	2,131	2,437	2,801	3,052	3,576
230	1,250	1,787	2,129	2,435	2,798	3,049	3,574
235	1,248	1,785	2,127	2,432	2,795	3,046	3,571
240	1,247	1,783	2,125	2,430	2,793	3,043	3,568
245	1,246	1,782	2,123	2,428	2,790	3,041	3,564
250	1,245	1,780	2,121	2,426	2,788	3,038	3,561
255	1,244	1,779	2,120	2,424	2,786	3,036	3,558
260	1,243	1,777	2,118	2,422	2,783	3,033	3,555
265	1,242	1,776	2,116	2,420	2,781	3,031	3,553
270	1,241	1,775	2,115	2,418	2,779	3,028	3,550
275	1,240	1,773	2,113	2,416	2,777	3,026	3,547
280	1,239	1,772	2,111	2,415	2,775	3,024	3,545
285	1,238	1,771	2,110	2,413	2,773	3,022	3,542
290	1,238	1,770	2,109	2,411	2,771	3,020	3,540
295	1,237	1,768	2,107	2,410	2,769	3,018	3,538
300	1,236	1,767	2,106	2,408	2,767	3,016	3,535
310	1,234	1,765	2,103	2,405	2,764	3,012	3,531
320	1,233	1,763	2,101	2,402	2,761	3,008	3,527
330	1,232	1,761	2,098	2,400	2,758	3,005	3,523
340	1,230	1,759	2,096	2,397	2,755	3,002	3,519

Table D.1 (continued)

<i>n</i>	Confidence = 95 %						
	<i>p</i> = 0,750	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995	<i>p</i> = 0,999
350	1,229	1,757	2,094	2,395	2,752	2,999	3,515
360	1,228	1,756	2,092	2,392	2,749	2,996	3,512
370	1,227	1,754	2,090	2,390	2,747	2,993	3,509
380	1,225	1,752	2,088	2,388	2,744	2,990	3,505
390	1,224	1,751	2,086	2,386	2,742	2,988	3,502
400	1,223	1,749	2,084	2,384	2,739	2,985	3,499
425	1,221	1,746	2,080	2,379	2,734	2,979	3,493
450	1,219	1,743	2,077	2,375	2,729	2,974	3,486
475	1,217	1,740	2,073	2,371	2,725	2,969	3,481
500	1,215	1,737	2,070	2,368	2,721	2,965	3,476
525	1,213	1,735	2,067	2,364	2,717	2,961	3,471
550	1,212	1,733	2,065	2,361	2,713	2,957	3,466
575	1,210	1,731	2,062	2,358	2,710	2,953	3,462
600	1,209	1,729	2,060	2,356	2,707	2,950	3,458
625	1,208	1,727	2,058	2,353	2,704	2,947	3,455
650	1,207	1,725	2,056	2,351	2,702	2,944	3,451
700	1,204	1,722	2,052	2,347	2,697	2,939	3,445
750	1,202	1,719	2,049	2,343	2,692	2,934	3,439
800	1,201	1,717	2,046	2,339	2,688	2,930	3,434
850	1,199	1,715	2,043	2,336	2,685	2,926	3,430
900	1,198	1,712	2,040	2,333	2,682	2,922	3,426
950	1,196	1,711	2,038	2,331	2,679	2,919	3,422
1000	1,195	1,709	2,036	2,328	2,676	2,916	3,418
1500	1,186	1,697	2,022	2,312	2,657	2,895	3,394
8	1,150	1,645	1,960	2,241	2,576	2,807	3,291

Annex E (informative)

Alternative acceptance criteria for the device functionality profile evaluation

E.1 General

The device functionality profile requirement is that there shall be 95 % confidence that at least p of all values will fall between the previously determined specification limits for the relevant P_T .

While the acceptance criterion based on a statistical tolerance interval in 6.4.2 fulfills this requirement, it is also too conservative in the sense that the confidence is generally higher than 95 %. This means a higher risk of failing due to chance, even if the system is technically acceptable.

A more precise acceptance criterion is based on estimating the proportion of values within the specification limits, \hat{p} , and accepting if this is larger than a pre-specified constant p^* . The latter depends on the sample size, n , probability content, p , and the confidence level (95 %), and is tabulated in Table E.1.

More specifically the test is conducted as follows. Denote the distribution of the symmetrical beta distribution by:

$$B_m(y) = \begin{cases} 0 & \text{if } y < 0, \\ \int_0^y \frac{t^{m-1}(1-t)^{m-1}}{B(m,m)} dt & \text{if } 0 \leq y \leq 1 \\ 1 & \text{if } y > 1 \end{cases} \quad (\text{E.1})$$

where $B(m,m) = \Gamma(m)\Gamma(m)/\Gamma(2m)$, with $\Gamma(m)$ representing the gamma function, i.e.

$$\Gamma(m) = \int_0^\infty x^{m-1} e^{-x} dx \quad (\text{E.2})$$

The proportion of values below the lower specification limit is then estimated by

$$\hat{p}_L = B_{(n-2)/2} \left[\frac{1}{2} \left(1 - \frac{\bar{x} - \text{LSL}}{s} \frac{\sqrt{n}}{n-1} \right) \right] \quad (\text{E.3})$$

and the proportion above the upper limit is estimated by

$$\hat{p}_U = B_{(n-2)/2} \left[\frac{1}{2} \left(1 - \frac{\text{USL} - \bar{x}}{s} \frac{\sqrt{n}}{n-1} \right) \right] \quad (\text{E.4})$$


The proportion of values falling within the limits is thus given by

$$\hat{p} = 1 - (\hat{p}_L + \hat{p}_U) \quad (\text{E.5})$$

The test is passed if $\hat{p} \geq p^*$. A table of p^* values is presented as Table E.1.

To compute the test, the distribution of the symmetrical beta distribution must be used. This is available in common computer software packages, or in some statistical tables. If none of these are available, an approximate formula may be used instead, which for all practical purposes gives the same result [Baillie 1997, see also ISO 3951-2].

A comparison of the p^* -method presented in this annex with the k -method from 6.4.2 is given below for $p = 0,95$ and $0,975$ and $n = 50$. The figures show the acceptance region of the tests, i.e. the results that lead to acceptance in the space of the sample mean and standard deviation in percent of target. The p^* -method generally provides a larger acceptance area than the k -method, and thus a higher chance of passing, without compromising the statistical requirements in the device functionality profile.



Key

- X sample mean (% of target)
- Y sample standard deviation (% of target)
- 1 k method
- 2 p^* method

Figure E.1 — Acceptance regions

Table E.1 — Values of $100 \times p^*$ (confidence level 95 %)

<i>n</i>	Probability content						
	<i>p</i> = 0,750	<i>p</i> = 0,850	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995
3	100,000	100,000	100,000	100,000	100,000	100,000	100,000
4	100,000	100,000	100,000	100,000	100,000	100,000	100,000
5	100,000	100,000	100,000	100,000	100,000	100,000	100,000
6	99,625	100,000	100,000	100,000	100,000	100,000	100,000
7	97,720	100,000	100,000	100,000	100,000	100,000	100,000
8	96,064	99,815	100,000	100,000	100,000	100,000	100,000
9	94,720	99,319	99,979	100,000	100,000	100,000	100,000
10	93,609	98,769	99,844	100,000	100,000	100,000	100,000
11	92,672	98,241	99,637	99,999	100,000	100,000	100,000
12	91,868	97,753	99,404	99,985	100,000	100,000	100,000
13	91,167	97,307	99,166	99,952	100,000	100,000	100,000
14	90,549	96,902	98,933	99,905	99,999	100,000	100,000
15	89,999	96,531	98,710	99,849	99,994	100,000	100,000
16	89,504	96,192	98,498	99,787	99,986	100,000	100,000
17	89,056	95,881	98,298	99,721	99,975	100,000	100,000
18	88,648	95,594	98,110	99,654	99,960	100,000	100,000
19	88,274	95,328	97,932	99,587	99,944	99,999	100,000
20	87,930	95,082	97,765	99,521	99,926	99,998	100,000
21	87,611	94,852	97,608	99,455	99,906	99,996	100,000
22	87,316	94,637	97,459	99,391	99,886	99,993	100,000
23	87,040	94,436	97,318	99,329	99,865	99,990	100,000
24	86,783	94,247	97,185	99,269	99,844	99,987	99,999
25	86,541	94,069	97,059	99,210	99,822	99,983	99,998
26	86,314	93,901	96,939	99,154	99,801	99,979	99,998
27	86,100	93,742	96,824	99,099	99,779	99,974	99,997
28	85,897	93,592	96,716	99,046	99,758	99,970	99,996
29	85,706	93,449	96,612	98,995	99,737	99,965	99,994
30	85,524	93,313	96,513	98,946	99,716	99,960	99,993
31	85,351	93,183	96,418	98,898	99,696	99,955	99,992
32	85,187	93,059	96,327	98,852	99,676	99,950	99,990
33	85,030	92,941	96,241	98,807	99,656	99,945	99,988
34	84,881	92,828	96,157	98,763	99,637	99,939	99,987
35	84,738	92,720	96,077	98,722	99,618	99,934	99,985
36	84,601	92,616	96,000	98,681	99,600	99,929	99,983
37	84,469	92,516	95,926	98,642	99,582	99,923	99,981
38	84,343	92,420	95,854	98,603	99,564	99,918	99,980
39	84,222	92,328	95,785	98,566	99,547	99,913	99,978
40	84,106	92,239	95,719	98,531	99,530	99,907	99,976

Table E.1 (continued)

<i>n</i>	Probability content						
	<i>p</i> = 0,750	<i>p</i> = ,850	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995
41	83,994	92,154	95,654	98,496	99,513	99,902	99,974
42	83,886	92,071	95,592	98,462	99,497	99,897	99,972
43	83,781	91,991	95,532	98,429	99,481	99,892	99,970
44	83,681	91,914	95,474	98,397	99,465	99,887	99,968
45	83,584	91,839	95,418	98,366	99,450	99,882	99,966
46	83,489	91,767	95,363	98,336	99,435	99,877	99,964
47	83,399	91,697	95,310	98,306	99,420	99,872	99,962
48	83,310	91,629	95,259	98,277	99,406	99,867	99,960
49	83,225	91,564	95,209	98,249	99,392	99,862	99,958
50	83,142	91,500	95,160	98,222	99,378	99,857	99,956
51	83,062	91,438	95,113	98,196	99,365	99,852	99,954
52	82,984	91,377	95,067	98,170	99,352	99,848	99,952
53	82,908	91,319	95,022	98,144	99,339	99,843	99,950
54	82,835	91,262	94,979	98,120	99,326	99,838	99,948
55	82,763	91,207	94,936	98,096	99,314	99,834	99,946
56	82,693	91,153	94,895	98,072	99,302	99,829	99,945
57	82,626	91,100	94,855	98,049	99,290	99,825	99,943
58	82,560	91,049	94,816	98,026	99,278	99,821	99,941
59	82,495	90,999	94,777	98,004	99,267	99,817	99,939
60	82,433	90,950	94,740	97,983	99,255	99,812	99,937
61	82,371	90,903	94,703	97,962	99,244	99,808	99,935
62	82,312	90,856	94,668	97,941	99,234	99,804	99,933
63	82,254	90,811	94,633	97,921	99,223	99,800	99,932
64	82,197	90,767	94,599	97,901	99,213	99,796	99,930
65	82,141	90,723	94,566	97,882	99,202	99,792	99,928
66	82,087	90,681	94,533	97,863	99,192	99,788	99,926
67	82,034	90,640	94,501	97,844	99,182	99,784	99,925
68	81,982	90,599	94,470	97,826	99,173	99,781	99,923
69	81,931	90,560	94,439	97,808	99,163	99,777	99,921
70	81,882	90,521	94,409	97,791	99,154	99,773	99,920
71	81,833	90,483	94,380	97,773	99,144	99,770	99,918
72	81,786	90,446	94,351	97,756	99,135	99,766	99,916
73	81,739	90,409	94,323	97,740	99,126	99,762	99,915
74	81,693	90,374	94,295	97,723	99,118	99,759	99,913
75	81,649	90,339	94,268	97,707	99,109	99,756	99,911
76	81,605	90,304	94,242	97,692	99,101	99,752	99,910
77	81,562	90,271	94,215	97,676	99,092	99,749	99,908
78	81,520	90,238	94,190	97,661	99,084	99,746	99,907

Table E.1 (continued)

<i>n</i>	Probability content						
	<i>p</i> = 0,750	<i>p</i> = ,850	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995
79	81,478	90,205	94,165	97,646	99,076	99,742	99,905
80	81,438	90,174	94,140	97,632	99,068	99,739	99,904
81	81,398	90,142	94,116	97,617	99,060	99,736	99,902
82	81,359	90,112	94,092	97,603	99,052	99,733	99,901
83	81,321	90,082	94,068	97,589	99,045	99,730	99,899
84	81,283	90,052	94,045	97,575	99,037	99,727	99,898
85	81,246	90,023	94,023	97,562	99,030	99,724	99,896
86	81,210	89,994	94,001	97,549	99,022	99,721	99,895
87	81,174	89,966	93,979	97,535	99,015	99,718	99,893
88	81,139	89,939	93,957	97,523	99,008	99,715	99,892
89	81,104	89,912	93,936	97,510	99,001	99,712	99,891
90	81,070	89,885	93,915	97,497	98,994	99,709	99,889
91	81,037	89,859	93,895	97,485	98,987	99,706	99,888
92	81,004	89,833	93,875	97,473	98,981	99,703	99,886
93	80,972	89,807	93,855	97,461	98,974	99,701	99,885
94	80,940	89,782	93,835	97,449	98,968	99,698	99,884
95	80,909	89,758	93,816	97,438	98,961	99,695	99,882
96	80,878	89,734	93,797	97,426	98,955	99,692	99,881
97	80,848	89,710	93,778	97,415	98,949	99,690	99,880
98	80,818	89,686	93,760	97,404	98,942	99,687	99,879
99	80,789	89,663	93,742	97,393	98,936	99,685	99,877
100	80,760	89,640	93,724	97,382	98,930	99,682	99,876
102	80,703	89,595	93,689	97,361	98,919	99,677	99,874
104	80,648	89,552	93,655	97,341	98,907	99,672	99,871
106	80,595	89,510	93,622	97,320	98,896	99,668	99,869
108	80,543	89,469	93,590	97,301	98,885	99,663	99,867
110	80,492	89,429	93,558	97,282	98,874	99,658	99,864
112	80,443	89,390	93,528	97,263	98,864	99,654	99,862
114	80,395	89,352	93,498	97,245	98,853	99,649	99,860
116	80,349	89,316	93,469	97,228	98,843	99,645	99,858
118	80,303	89,280	93,441	97,210	98,834	99,641	99,856
120	80,259	89,245	93,413	97,193	98,824	99,637	99,853
122	80,216	89,210	93,387	97,177	98,815	99,633	99,851
124	80,174	89,177	93,360	97,161	98,806	99,629	99,849
126	80,133	89,144	93,335	97,145	98,797	99,625	99,847
128	80,093	89,113	93,310	97,130	98,788	99,621	99,845
130	80,053	89,081	93,285	97,115	98,779	99,617	99,844
132	80,015	89,051	93,261	97,100	98,771	99,614	99,842

Table E.1 (continued)

<i>n</i>	Probability content						
	<i>p</i> = 0,750	<i>p</i> = ,850	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995
134	79,978	89,021	93,238	97,086	98,763	99,610	99,840
136	79,941	88,992	93,215	97,071	98,755	99,606	99,838
138	79,905	88,964	93,192	97,058	98,747	99,603	99,836
140	79,870	88,936	93,170	97,044	98,739	99,599	99,834
142	79,836	88,909	93,149	97,031	98,731	99,596	99,833
144	79,802	88,882	93,128	97,018	98,724	99,593	99,831
146	79,769	88,856	93,107	97,005	98,717	99,590	99,829
148	79,737	88,830	93,087	96,992	98,709	99,586	99,828
150	79,705	88,805	93,067	96,980	98,702	99,583	99,826
152	79,674	88,781	93,047	96,968	98,695	99,580	99,824
154	79,644	88,756	93,028	96,956	98,688	99,577	99,823
156	79,614	88,733	93,010	96,945	98,682	99,574	99,821
158	79,585	88,709	92,991	96,933	98,675	99,571	99,820
160	79,556	88,687	92,973	96,922	98,669	99,568	99,818
162	79,528	88,664	92,955	96,911	98,662	99,565	99,817
164	79,501	88,642	92,938	96,900	98,656	99,562	99,815
166	79,474	88,621	92,921	96,890	98,650	99,560	99,814
168	79,447	88,599	92,904	96,879	98,644	99,557	99,812
170	79,421	88,579	92,887	96,869	98,638	99,554	99,811
172	79,395	88,558	92,871	96,859	98,632	99,552	99,810
174	79,370	88,538	92,855	96,849	98,626	99,549	99,808
176	79,345	88,518	92,839	96,839	98,620	99,546	99,807
178	79,321	88,499	92,824	96,829	98,615	99,544	99,806
180	79,297	88,480	92,809	96,820	98,609	99,541	99,804
185	79,238	88,433	92,772	96,797	98,596	99,535	99,801
190	79,182	88,388	92,736	96,775	98,583	99,529	99,798
195	79,129	88,345	92,702	96,753	98,570	99,524	99,795
200	79,077	88,304	92,669	96,733	98,558	99,518	99,792
205	79,027	88,264	92,638	96,713	98,547	99,513	99,789
210	78,979	88,226	92,607	96,693	98,536	99,508	99,786
215	78,933	88,189	92,578	96,675	98,525	99,503	99,784
220	78,888	88,153	92,549	96,657	98,514	99,498	99,781
225	78,844	88,118	92,521	96,640	98,504	99,493	99,779
230	78,803	88,085	92,495	96,623	98,494	99,489	99,776
235	78,762	88,052	92,469	96,606	98,484	99,484	99,774
240	78,723	88,021	92,444	96,591	98,475	99,480	99,771
245	78,685	87,990	92,419	96,575	98,466	99,476	99,769
250	78,648	87,961	92,396	96,560	98,457	99,471	99,767

Table E.1 (continued)

<i>n</i>	Probability content						
	<i>p</i> = 0,750	<i>p</i> = ,850	<i>p</i> = 0,900	<i>p</i> = 0,950	<i>p</i> = 0,975	<i>p</i> = 0,990	<i>p</i> = 0,995
255	78,612	87,932	92,373	96,546	98,448	99,467	99,765
260	78,577	87,904	92,351	96,532	98,440	99,464	99,763
265	78,543	87,877	92,329	96,518	98,432	99,460	99,761
270	78,511	87,850	92,308	96,505	98,424	99,456	99,759
275	78,479	87,825	92,287	96,492	98,416	99,452	99,757
280	78,447	87,800	92,267	96,479	98,409	99,449	99,755
285	78,417	87,776	92,248	96,467	98,401	99,445	99,753
290	78,388	87,752	92,229	96,455	98,394	99,442	99,751
295	78,359	87,729	92,211	96,443	98,387	99,439	99,749
300	78,331	87,706	92,193	96,431	98,381	99,436	99,748
310	78,277	87,663	92,158	96,409	98,367	99,429	99,744
320	78,226	87,622	92,125	96,388	98,355	99,423	99,741
330	78,176	87,582	92,093	96,368	98,343	99,418	99,738
340	78,130	87,544	92,063	96,349	98,331	99,412	99,735
350	78,085	87,508	92,034	96,330	98,320	99,407	99,732
360	78,042	87,474	92,006	96,313	98,310	99,402	99,729
370	78,000	87,440	91,979	96,296	98,299	99,397	99,727
380	77,961	87,408	91,954	96,279	98,289	99,392	99,724
390	77,923	87,378	91,929	96,263	98,280	99,388	99,721
400	77,886	87,348	91,906	96,248	98,271	99,384	99,719
425	77,800	87,279	91,850	96,213	98,249	99,373	99,713
450	77,721	87,215	91,799	96,180	98,230	99,364	99,708
475	77,649	87,157	91,752	96,150	98,211	99,355	99,703
500	77,582	87,103	91,708	96,122	98,195	99,347	99,699
525	77,520	87,053	91,668	96,096	98,179	99,339	99,695
550	77,462	87,006	91,630	96,071	98,164	99,332	99,691
575	77,408	86,963	91,595	96,049	98,150	99,326	99,687
600	77,358	86,922	91,562	96,027	98,137	99,319	99,683
625	77,310	86,883	91,531	96,007	98,125	99,313	99,680
650	77,265	86,847	91,502	95,988	98,114	99,308	99,677
700	77,183	86,781	91,448	95,954	98,093	99,298	99,671
750	77,109	86,721	91,400	95,922	98,073	99,288	99,666
800	77,043	86,667	91,356	95,894	98,056	99,280	99,661
850	76,982	86,617	91,317	95,868	98,040	99,272	99,657
900	76,926	86,572	91,280	95,844	98,026	99,265	99,653
950	76,875	86,531	91,246	95,822	98,012	99,258	99,649
1 000	76,827	86,492	91,215	95,802	98,000	99,252	99,646
1 500	76,493	86,220	90,995	95,658	97,911	99,208	99,621

Bibliography

- [1] ISO 3951-2, *Sampling procedures for inspection by variables — Part 2: General specification for single sampling plans indexed by acceptance quality limit (AQL) for lot-by-lot inspection of independent quality characteristics*
- [2] ISO 15378, *Primary packaging materials for medicinal products — Particular requirements for the application of ISO 9001:2000, with reference to Good Manufacturing Practice (GMP)*
- [3] ISO 27427, *Anaesthetic and respiratory equipment — Nebulizing systems and components*
- [4] ISO 16269-6:2005, *Statistical interpretation of data — Part 6: Determination of statistical tolerance intervals*
- [5] ISO 13485, *Medical devices — Quality management systems — Requirements for regulatory purposes*
- [6] IEC 61000-4-1, *Electromagnetic compatibility (EMC) — Part 4-1: Testing and measurement techniques — Overview of IEC 61000-4 series*
- [7] USFDA *Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators*, 1993. (<http://www.fda.gov/cdrh/ode/784.pdf>)
- [8] USFDA Guidance for Industry: *Integration of Dose-Counting Mechanisms into MDI Drug Products*, 2003. (<http://www.fda.gov/cder/guidance/5308FNL.pdf>)
- [9] USFDA Guidance for Industry: *Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation — Small Entity Compliance Guide*, 2001. (<http://www.fda.gov/cder/guidance/4774fnl.pdf>)
- [10] USFDA Draft Guidance for Industry: *Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation*, 1998. (<http://www.fda.gov/cder/guidance/2180dft.htm>)
- [11] USFDA Guidance for Industry: *Nasal Spray and Inhalation Solution, Suspension and Spray Drug Products — Chemistry, Manufacturing and Controls Documentation*, 2002. (<http://www.fda.gov/cder/guidance/4234fnl.pdf>)
- [12] Global Harmonization Task Force (GHTF): *Implementation of Risk Management Principles and Activities within a Quality Management System*, GHTF/SG3/N15R8, 2005. (<http://www.ghrf.org/sg3/inventorysg3/sg3n15r82005.pdf>)
- [13] CAN/CSA/Z264.1-02:2002, *Spacers and holding chambers for use with metered-dose Inhalers*, Canadian Standards Association, Mississauga, Ont., Canada, 2002
- [14] EMEA & Health Canada: *Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products*, 2006. (<http://www.emea.eu.int/pdfs/human/qwp/4931305en.pdf>)
- [15] European Pharmacopeia; Dosage Forms — *Preparations for inhalation (Inhalanda)*, European Pharmacopeia: 5th Edn., Council of Europe, 67075 Strasbourg, pp. 618-622, 2005
- [16] European Pharmacopeia; Section 2.9.18 — *Preparations for inhalation: aerodynamic assessment of fine particles*. European Pharmacopeia: 5th Edn., Council of Europe, 67075 Strasbourg, pp. 2799-2811, 2005
- [17] United States Pharmacopeia; USP 30-NF 25; Chapter 601 — *Physical tests and determinations: Aerosols*. United States Pharmacopeia, Rockville, MD, USA., pp. 220-240, 2007

- [18] LIEBERMAN, G. J. and RESNIKOFF, G. J., *Sampling plans for inspection by variables*, American Statistical Association Journal, pp. 457-516, 1995

- [19] BAILLIE, D.H., *Normal Approximations to the Distribution Function of the Symmetric Beta Distribution*, *Frontiers in Statistical Quality Control*, **5**, LENZ et al., (eds.) pp. 52-65, Physica-Verlag, Heidelberg, 1997

ICS 11.040.10

Price based on 43 pages